The past couple weeks have been pretty wild with the criticized Lancet publication spurring the WHO pronouncement on Wednesday to temporarily suspend the testing of HCQ in Covid-19 patients following safety concerns. It resulted in nations around the globe taking sides this week as to whether they were abandoning use of HCQ and halting study trials, or forging ahead with it based on their own medical community determinations of safety and benefit through first hand treatment of their populations.
India's ICMR finds it safe and is forging ahead with HCQ
Lancet spooked Canada, but after a pause, found no safety issues and resumed their 9 ongoing trials.
German clinical trial of HCQ paused even though director sees "no evidence of side effects" and is confident that it will resume shortly. (subscription)
More responsive to your question - treatment benefits beyond primary safety questions - Turkey is also forging ahead with HCQ and appears to have it dialed in:
The article has a section dedicated debate over HCQ. From the article:
"Chief doctor Nurettin Yiyit - whose art work is on the hospital walls - says it's key to use hydroxychloroquine early. "Other countries are using this drug too late," he says, "especially the United States. We only use it at the beginning. We have no hesitation about this drug. We believe it's effective because we get the results."
They are all saying early application is key, not after you've been symptomatic for a week or had progression of severity requiring hospitalization. This is the common observation and practice in Italy, India, Turkey, other European countries, and in various nations in SE Asia. So far Zinc is not even a part of MSM reporting on this matter. However, there has been one study (non-gold standard) to date out of NYU the other week suggesting Zn added to the HCQ appeared to have a sizable benefit.